GIP and obesity due to melanocortin 4 receptor deficiency: Tirzepatide, a novel dual agonist targeting glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors marketed as Zepbound by its manufacturer Eli Lilly and Company, has shown significant efficacy in managing type 2 diabetes mellitus (T2DM) and obesity, as demonstrated in key clinical trials such as SURPASS [1] and SURMOUNT [2].